- Nachrichtendetail
-
01.04.2024 14:15:09 - dpa-AFX: *VERTEX ADVANCES INAXAPLIN INTO PHASE 3 PORTION OF PHASE 2/3 TRIAL FOR TREATMENT OF APOL1-MEDIATED KIDNEY DISEASE
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
VERTEX PHARMAC. DL-,01 | 882807 | Xetra | 446,900 | 27.06.24 13:37:45 | +1,900 | +0,43% | 443,200 | 446,800 | 443,900 | 445,000 |
